We are live on ! Find out more
PCM

Perkins Capital Management Portfolio holdings

AUM $133M Turnover 16.67%
1-Year Est. Return 127.86%
This Fund
S&P 500
This Quarter Est. Return
+17.18%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$109M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow %
98.65%
Top 10 Hldgs %
40.45%
Holding
93
New
93
Increased
–
Reduced
–
Closed
–
Avg Time Held
3.2 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
2.1 years

Top Buys

Rank Stock Value
1
NEO icon
NeoGenomics
NEO
+$7.42M
2
VCEL icon
Vericel Corp
VCEL
+$4.58M
3
VCYT icon
Veracyte
VCYT
+$4.15M
4
IDXX icon
Idexx Laboratories
IDXX
+$4.14M
5
CDNA icon
CareDx
CDNA
+$4.04M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 68.08%
2 Technology 13.91%
3 Communication Services 6.99%
4 Industrials 4.39%
5 Consumer Staples 4.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NEO icon
1
NeoGenomics
NEO
$2.22B
$7.36M 6.76%
+199,525
New +$7.42M
2013 Q2
29 quarters
VCEL icon
2
Vericel Corp
VCEL
$2.1B
$5.13M 4.71%
+276,897
New +$4.58M
2014 Q3
24 quarters
NTRA icon
3
Natera
NTRA
$58.3B
$5.11M 4.69%
+70,700
New +$4.02M
2018 Q2
9 quarters
CDNA icon
4
CareDx
CDNA
$3.45B
$4.54M 4.17%
+119,592
New +$4.04M
2017 Q3
12 quarters
IDXX icon
5
Idexx Laboratories
IDXX
$43.1B
$4.41M 4.05%
+11,205
New +$4.14M
2013 Q3
28 quarters
VCYT icon
6
Veracyte
VCYT
$3.57B
$4.24M 3.9%
+130,580
New +$4.15M
2018 Q1
10 quarters
OPRX icon
7
OptimizeRx
OPRX
$167M
$3.52M 3.23%
+168,760
New +$2.9M
2018 Q2
9 quarters
MSFT icon
8
Microsoft
MSFT
$4.01T
$3.36M 3.09%
+15,993
New +$3.36M
2014 Q1
26 quarters
AXGN icon
9
Axogen
AXGN
$2.09B
$3.33M 3.06%
+286,190
New +$3.32M
2013 Q3
28 quarters
ABT icon
10
Abbott
ABT
$181B
$3.05M 2.8%
+28,030
New +$2.84M
2014 Q1
26 quarters
LAB icon
11
Standard BioTools
LAB
$258M
$2.47M 2.27%
+332,425
New +$2.29M
2017 Q4
11 quarters
FPAY icon
12
DELISTED
FlexShopper
FPAY
$2.15M 1.98%
+1,217,130
New +$2.08M
2018 Q3
8 quarters
CSII
13
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.14M 1.97%
+54,450
New +$1.76M
2013 Q2
29 quarters
LLY icon
14
Eli Lilly
LLY
$1.12T
$2.07M 1.9%
+13,958
New +$2.16M
2013 Q2
29 quarters
RMTI icon
15
Rockwell Medical
RMTI
$32.2M
$1.97M 1.81%
+16,766
New +$2.9M
2013 Q2
29 quarters
MGNI icon
16
Magnite
MGNI
$3.51B
$1.92M 1.77%
+277,000
New +$1.85M
2018 Q2
9 quarters
LMAT icon
17
LeMaitre Vascular
LMAT
$1.9B
$1.84M 1.69%
+56,700
New +$1.7M
2017 Q1
14 quarters
BLFS icon
18
DELISTED
BioLife Solutions
BLFS
$1.84M 1.69%
+63,650
New +$1.37M
2014 Q2
25 quarters
CSTL icon
19
Castle Biosciences
CSTL
$1.03B
$1.8M 1.65%
+34,900
New +$1.55M
2019 Q3
4 quarters
PFE icon
20
Pfizer
PFE
$168B
$1.77M 1.63%
+50,985
New +$1.79M
2013 Q2
29 quarters
ATRC icon
21
AtriCure
ATRC
$2.94B
$1.77M 1.63%
+44,350
New +$1.88M
2013 Q2
29 quarters
ASPU
22
DELISTED
ASPEN GROUP, INC.
ASPU
$1.71M 1.57%
+152,750
New +$1.63M
2019 Q4
3 quarters
INUV icon
23
Inuvo
INUV
$7.58M
$1.7M 1.56%
+464,021
New +$2.3M
2018 Q2
9 quarters
QUMU
24
DELISTED
Qumu Corp.
QUMU
$1.66M 1.53%
+361,000
New +$1.82M
2019 Q4
3 quarters
AKTS icon
25
DELISTED
Akoustis Technologies Inc
AKTS
$1.59M 1.46%
+195,300
New +$1.58M
2018 Q4
7 quarters
1
2 3 4

Similar funds

AA
Alpha Advisors Richmond, Virginia $133M AUM 20.23% 1-Year Est. Return
WA
Winter & Associates St. Paul, Minnesota $133M AUM
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return
BCVI
Bain Capital Venture Investors Boston, Massachusetts $133M AUM 50.19% 1-Year Est. Return
HAP
Harbor Asset Planning Belmont, Massachusetts $133M AUM 24.86% 1-Year Est. Return
RHIG
R.H. Investment Group Scottsdale, Arizona $133M AUM 23.61% 1-Year Est. Return
CWM
Capstone Wealth Management Billings, Montana $133M AUM
SI
Severin Investments St. Louis, Missouri $133M AUM 45.69% 1-Year Est. Return

Perkins Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Perkins Capital Management held 93 positions worth $109M. Its ten largest holdings account for 40% of the portfolio.

Perkins Capital Management deployed $107M of net new capital in Q3 2020, opening 93 new positions. Its largest new stake was NeoGenomics: 199,525 shares worth $7.36M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, followed by Technology and Communication Services.

  • Perkins Capital Management's largest Q3 2020 buy was NeoGenomics: 199,525 shares worth $7.36M.
  • Perkins Capital Management's ten largest holdings make up 40% of its $109M portfolio in Q3 2020.
  • Perkins Capital Management opened 93 new positions and closed 0 in Q3 2020.

Based on Perkins Capital Management's 13F filing for Q3 2020, filed 28 Oct 2020.